Skip to main content
. 2017 Dec 21;110(7):750–757. doi: 10.1093/jnci/djx263

Table 3.

Age-standardized, cause-specific survival (% surviving to 60 months), stage- and histology-specific estimates overall and by age strata (North American Association of Central Cancer Registries, 1999–2012)*

C57.0 Fallopian tube
C56.9 Ovary
Characteristic No. % (95% CI) No. % (95% CI)
In situ 164 97.9 (93.7 to 99.3)
 <50 y 61 100
 50+ y 103 96.8 (90.3 to 98.9)
Early-stage/low-grade serous 106 83.4 (72.3 to 90.3) 1247 90.7 (88.7 to 92.3)
 <50 y <16 394 96.3 (93.6 to 97.9)
 50+ y 91 84.3 (72.5 to 91.3) 853 88.1 (85.4 to 90.3)
Early-stage/high-grade serous 357 83.2 (77.3 to 87.7) 1198 85.2 (82.7 to 87.4)
 <50 y 45 80.4 (58.7 to 91.5) 230 88.4 (82.6 to 92.4)
 50+ y 312 83.8 (77.6 to 88.4) 968 84.4 (81.5 to 86.9)
Late-stage/low-grade serous 218 42.1 (34.1 to 49.9) 8001 46.1 (44.9 to 47.3)
 <50 y 27 52.2 (30.1 to 70.3) 1974 63.5 (61.0 to 65.8)
 50+ y 191 40.6 (32.0 to 49.0) 6027 40.5 (39.1 to 41.8)
Late-stage/high-grade serous 1605 44.5 (41.1 to 47.7) 29 685 33.8 (33.2 to 34.4)
 <50 y 166 58.7 (48.0 to 67.9) 4358 44.0 (42.2 to 45.7)
 50+ y 1439 42.7 (39.2 to 46.2) 25 327 32.0 (31.3 to 32.7)
*

Cause of death was defined as fallopian tube cancer or ovarian cancer, respectively, using the Surveillance, Epidemiology, and End Results cause-specific death classification variable (21). Cancer cases were excluded if not first tumor, if missing age at diagnosis, or if follow-up was missing or 0. CI = confidence interval.

Cell count <16, frequencies, and percent surviving are not reported.